

Hexima Limited

ABN 64 079 319 314

La Trobe Institute for Molecular Science
Level 4, LIMS2, Plenty Road
La Trobe University VIC 3086 Australia**P** 61 3 9479 1210**F** 61 3 9479 1266**E** info@hexima.com.auhexima.com.au

Dear shareholders,

Re: Hexima's Annual General Meeting

It is our pleasure to invite you to Hexima's Annual General Meeting to be held at 3.30pm on the 19th November 2019, at Minter Ellison, Level 23, Rialto Towers, 525 Collins Street Melbourne. The formal business of the meeting is outlined in the attached Notice of Meeting.

In addition to the formal business, we will be providing an update on our progress for the 2018-2019 financial year including positive results from our first-in-human clinical trial for our lead drug candidate, HXP124.

HXP124 is an antifungal plant defensin which has been formulated for efficient nail penetration and is expected to reach the site of infection in amounts that effectively kill the fungi that are responsible for the infection. Furthermore, HXP124 has a fungicidal mode-of-action and kills fungal cells within 30 minutes. Together, we believe these attributes will make HXP124 a best-in-class treatment for fungal nail infections.

Positive clinical data is a key development for Hexima and provides proof-of-concept evidence for the potential of HXP124 to be a novel and effective treatment for onychomycosis.

We will also provide an update of the market opportunity for HXP124 in the United States as well as our strategy to advance HXP124 into phase IIb clinical trials in the coming years.

We look forward to seeing you on November 19.

Sincerely



Jonathan West



Nicole van der Weerden